Buy Venclexta Near Me – Targeted Treatment for Chronic Lymphocytic Leukemia (CLL)
What is Venclexta?
Venclexta is an oral medication used to treat Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML). This groundbreaking treatment works by inhibiting the BCL-2 protein, which plays a significant role in preventing cancer cells from self-destruction. By targeting this pathway, Venclexta effectively induces apoptosis (programmed cell death) in cancer cells, leading to their reduction. Patients with CLL and AML who have not responded to other treatments may find Venclexta highly beneficial.
Venclexta (venetoclax) may be used to treat individuals with specific blood malignancies, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or newly diagnosed acute myeloid leukemia (AML), who are 75 years or older or have other comorbidities that exclude intense chemotherapy. Venclexta is used to treat AML in combination with azacitidine, decitabine, or low-dose cytarabine.
Venclexta’s mechanism of action involves targeting a specific protein known as BCL-2. BCL-2 works as a cell’s death switch, inhibiting planned cell death (apoptosis). Cancerous blood cells, notably in CLL, SLL, and AML, frequently overproduce BCL-2, rendering them resistant to conventional chemotherapy. Venclexta binds directly to BCL-2, reactivating the cell’s death switch and inducing apoptosis. Venclexta is not chemotherapy; rather, it is a focused treatment.
How Venclexta Works
Venclexta targets and blocks the function of the BCL-2 protein, which helps cancer cells survive longer than they should. By inhibiting BCL-2, Venclexta helps trigger cell death in cancerous cells. This mechanism of action makes it particularly effective in treating blood cancers like CLL and AML. Treatment plans for Venclexta are individualized, with specific dosing protocols based on the patient’s condition, including combination therapies for greater effectiveness.
How should I take Venclexta?
Take Venclexta exactly as directed by your doctor. Follow the recommendations on your prescription label and read any drug guidelines or instruction sheets. Your doctor may occasionally adjust your dosage.
- Venclexta is normally taken once a day.
- Venclexta dose starts with a 5-week ramp-up (see dosing details below).
- Your healthcare practitioner will advise you on the appropriate Venclexta dosage. Your dose is normally started low and gradually increased over several weeks.
- Your first dose may be administered in a hospital or clinic environment to promptly treat any major adverse effects.
Venclexta should be taken with food and drink at the same time every day.
- Do not chew, crush, or break a tablet. Swallow the tablet whole.
- Tell your doctor if you have difficulty swallowing the 100 mg Venclexta tablets. Your dose may be prescribed in smaller pills.
- To avoid possible adverse effects, drink 6 to 8 glasses of water per day for two days before starting Venclexta. Also, drink 6 to 8 glasses of water on the first day you take this medication and whenever your dose is adjusted.
- Venclexta is often given for 12 months in patients with untreated CLL or SLL. For different forms of blood malignancies, or in previously treated individuals, the Venclexta dosage may vary. How long have you to take Venclexta.
Venclexta Dosage
Recommended dosage of Venclexta for CLL/SLL
The dosage of Venclexta is normally gradually increased over 5 weeks, as specified in the Venclexta Package Insert:
- Week 1: Venclexta 20 mg 1 time a day
- Week 2: Venclexta 50 mg 1 time a day
- Week 3: Venclexta 100 mg 1 time a day
- Week 4: Venclexta 200 mg 1 time a day
- Week 5 and beyond: Vencelxta 400 mg 1 time a day.
The Venclexta Starting Pack includes the first four weeks of venetoclax based on the ramp-up program.
Venclexta’s continuous dosage is 400 mg once daily after the 5-week ramp-up dosing regimen is completed.
Venclexta should be used until the disease progresses or unacceptable toxicity occurs.
Recommended Venclexta dose for AML
- Day 1: Venclexta 100 mg 1 time a day
- Day 2: Venclexta 200 mg 1 time a day
- Day 3: Venclexta 400 mg 1 time a day
- Day 4 and beyond: Venclexta 400 mg once a day for 28 days in conjunction with azacitidine or decitabine; or Venclexta 600 mg once a day for 28 days in combination with low-dose cytarabine.
Venclexta should be used in combination with azacitidine, decitabine, or low-dose cytarabine until the disease progresses or intolerable toxicity occurs.
Venclexta ingredients
The active component is venetoclax.
Inactive components include copovidone, colloidal silicon dioxide, polysorbate 80, sodium stearyl fumarate, and calcium phosphate dibasic.
The film coating (10 mg and 100 mg tablets) contains iron oxide yellow, polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide.
The film coating (50 mg tablets) contains iron oxide yellow, iron oxide red, iron oxide black, polyvinyl alcohol, talc, polyethylene glycol, and titanium dioxide.
Tablets are available in strengths of 10 mg, 50 mg, and 100 mg.
Venclexta Side Effects
The most prevalent side effects of Venclexta include:
- Laboratory test changes, such as low white cell counts, low platelet counts, and low red blood cell counts
- Diarrhea
- Nausea
- Upper respiratory tract infections (such as a cold)
- Cough
- Muscle and joint pain
- Tiredness
Benefits of Venclexta in Leukemia Treatment
Venclexta provides significant hope for patients with CLL and AML by offering a targeted, non-chemotherapy option. It has been shown to help reduce cancerous cells and achieve remission in many patients. Its oral form makes it convenient, and it is often part of a combination treatment to improve efficacy. While Venclexta offers notable benefits, discussing potential Venclexta side effects, such as infections or low blood counts, with a healthcare provider is crucial for comprehensive care.
FAQ
Is Venclexta (venetoclax) chemotherapy?
No, Venclexta is not a chemotherapy medicine. It is a sort of focused treatment, not chemotherapy. Chemotherapy is a medicinal treatment that kills fast-growing cells in your body, including red blood cells and hair cells. Venclexta works by attaching to a protein called BCL-2, which is overexpressed on malignant cells in persons who have AML or CLL. By attaching to this protein, Venclexta destroys malignant CLL and AML lymphocytes rather than other cells.
Venclexta (venetoclax) is approved to treat AML in people aged 75 and up, as well as individuals with other medical issues that limit severe induction chemotherapy. It is used once a day with either azacytidine, decitabine, or low-dose cytarabine, and the tablets should be ingested whole rather than crushed, chewed, or broken.
What cancer does venetoclax treat?
How long can you be on VENCLEXTA?
VENCLEXTA is intended to be completed in a specific amount of time (12 months for previously untreated CLL/SLL when combined with GAZYVA or approximately 24 months for previously treated CLL/SLL when combined with rituximab), as opposed to some other oral medications that you take until your disease worsens.
Reviews
There are no reviews yet.